Context Therapeutics (CNTX) News Today $0.57 +0.01 (+1.58%) Closing price 04:00 PM EasternExtended Trading$0.60 +0.03 (+5.66%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Context Therapeutics Approves Reverse Stock Split AmendmentJune 12, 2025 | tipranks.comCo-Founder of Context Therapeutics Martin Lehr Buys 10% More SharesJune 11, 2025 | finance.yahoo.comContext Therapeutics Inc. (NASDAQ:CNTX) Insider Alex C. Levit Purchases 20,000 SharesJune 11, 2025 | insidertrades.comContext Therapeutics: Undervalued Cancer FighterJune 11, 2025 | seekingalpha.comInsider Buying: Context Therapeutics Inc. (NASDAQ:CNTX) Insider Buys 20,000 Shares of StockContext Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) insider Alex C. Levit purchased 20,000 shares of the firm's stock in a transaction dated Friday, June 6th. The shares were bought at an average price of $0.58 per share, with a total value of $11,600.00. Following the purchase, the insider now owns 29,000 shares in the company, valued at $16,820. This represents a 222.22% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.June 10, 2025 | marketbeat.comContext Therapeutics Inc. (NASDAQ:CNTX) CFO Acquires $25,606.40 in StockContext Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) CFO Jennifer Lynn Minai-Azary acquired 40,010 shares of the company's stock in a transaction that occurred on Friday, June 6th. The stock was acquired at an average price of $0.64 per share, with a total value of $25,606.40. Following the acquisition, the chief financial officer now owns 80,010 shares in the company, valued at $51,206.40. The trade was a 100.03% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.June 10, 2025 | marketbeat.comInsider Buying: Context Therapeutics Inc. (NASDAQ:CNTX) CEO Buys 100,000 Shares of StockContext Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) CEO Martin A. Lehr purchased 100,000 shares of the business's stock in a transaction on Monday, June 9th. The stock was acquired at an average price of $0.70 per share, with a total value of $70,000.00. Following the purchase, the chief executive officer now directly owns 920,190 shares in the company, valued at $644,133. This represents a 12.19% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.June 10, 2025 | marketbeat.comContext Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO MeetingJune 2, 2025 | globenewswire.comContext Therapeutics Inc.: Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical OfficerMay 29, 2025 | finanznachrichten.deContext Therapeutics Inc. Appoints Dr. Karen Chagin as Chief Medical OfficerMay 29, 2025 | quiverquant.comContext Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical OfficerMay 29, 2025 | globenewswire.comVelan Capital Investment Management LP Has $94,000 Stock Position in Context Therapeutics Inc. (NASDAQ:CNTX)Velan Capital Investment Management LP lowered its position in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 93.0% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 90,000 shares of the company's stock after selling 1May 22, 2025 | marketbeat.comMPM Bioimpact LLC Buys New Stake in Context Therapeutics Inc. (NASDAQ:CNTX)MPM Bioimpact LLC bought a new stake in Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 14,705,882 shares of the company's stock, valued at approximately $15,441,000. Context Therapeutics compriseMay 16, 2025 | marketbeat.comContext Therapeutics Inc. (NASDAQ:CNTX) Given Average Rating of "Buy" by BrokeragesShares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have received a consensus rating of "Buy" from the seven analysts that are covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation and one has given a strong buyMay 15, 2025 | marketbeat.comWilliam Blair Has Positive Outlook of CNTX FY2025 EarningsContext Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Equities researchers at William Blair increased their FY2025 earnings per share estimates for shares of Context Therapeutics in a report released on Wednesday, May 7th. William Blair analyst M. Phipps now forecasts that the company will earnMay 13, 2025 | marketbeat.comResearch Analysts Offer Predictions for CNTX Q2 EarningsContext Therapeutics Inc. (NASDAQ:CNTX - Free Report) - HC Wainwright lowered their Q2 2025 EPS estimates for shares of Context Therapeutics in a research note issued on Thursday, May 8th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.05) per share for the quarter, doMay 13, 2025 | marketbeat.comContext Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2025 | globenewswire.comContext Therapeutics Reports Q1 2025 Financial Results and Clinical ProgressMay 11, 2025 | msn.comD. Boral Capital Reiterates "Buy" Rating for Context Therapeutics (NASDAQ:CNTX)D. Boral Capital reissued a "buy" rating and set a $9.00 price target on shares of Context Therapeutics in a research report on Thursday.May 10, 2025 | marketbeat.comCONTEXT THERAPEUTICS Earnings Results: $CNTX Reports Quarterly EarningsMay 9, 2025 | nasdaq.comContext Therapeutics (CNTX) Expected to Announce Earnings on WednesdayContext Therapeutics (NASDAQ:CNTX) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-context-therapeutics-inc-stock/)May 9, 2025 | marketbeat.comContext Therapeutics Reports First Quarter 2025 Operating and Financial ResultsMay 7, 2025 | globenewswire.comContext Therapeutics Inc.: Context Therapeutics Announces Chief Medical Officer TransitionMay 7, 2025 | finanznachrichten.deContext Therapeutics Announces Chief Medical Officer TransitionMay 5, 2025 | tmcnet.comContext Therapeutics Announces Chief Medical Officer TransitionMay 5, 2025 | globenewswire.comAllostery Investments LP Purchases New Position in Context Therapeutics Inc. (NASDAQ:CNTX)Allostery Investments LP purchased a new position in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 950,166 shares of tMay 4, 2025 | marketbeat.comContext Therapeutics Showcases Promising CT-95 Data at AACR Annual MeetingMay 4, 2025 | msn.comEquities Analysts Issue Forecasts for CNTX Q2 EarningsContext Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Stock analysts at William Blair issued their Q2 2026 earnings per share estimates for shares of Context Therapeutics in a research report issued on Tuesday, April 29th. William Blair analyst M. Phipps forecasts that the company will post earMay 3, 2025 | marketbeat.comAnalysts Issue Forecasts for CNTX Q1 EarningsContext Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Equities researchers at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Context Therapeutics in a research report issued on Tuesday, April 29th. William Blair analyst M. Phipps anticipates that the company will postMay 2, 2025 | marketbeat.comContext Therapeutics (NASDAQ:CNTX) Receives "Outperform" Rating from William BlairWilliam Blair reissued an "outperform" rating on shares of Context Therapeutics in a report on Tuesday.May 1, 2025 | marketbeat.comD. Boral Capital Reaffirms Buy Rating for Context Therapeutics (NASDAQ:CNTX)D. Boral Capital restated a "buy" rating and set a $9.00 price objective on shares of Context Therapeutics in a report on Tuesday.May 1, 2025 | marketbeat.comContext Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual MeetingApril 30, 2025 | globenewswire.comBlue Owl Capital Holdings LP Acquires 946,638 Shares of Context Therapeutics Inc. (NASDAQ:CNTX)Blue Owl Capital Holdings LP raised its stake in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 17.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,357,928 shares of the company's stock after purchasinApril 26, 2025 | marketbeat.comQ1 Earnings Forecast for CNTX Issued By William BlairContext Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Investment analysts at William Blair issued their Q1 2025 EPS estimates for shares of Context Therapeutics in a research note issued on Monday, April 21st. William Blair analyst M. Phipps expects that the company will post earnings of ($0.05April 25, 2025 | marketbeat.comWilliam Blair starts Context Therapeutics stock with OutperformApril 23, 2025 | uk.investing.comContext Therapeutics (NASDAQ:CNTX) Now Covered by William BlairWilliam Blair started coverage on Context Therapeutics in a report on Monday. They set an "outperform" rating on the stock.April 23, 2025 | marketbeat.comWilliam Blair Initiates Coverage of Context Therapeutics (CNTX) with Outperform RecommendationApril 22, 2025 | msn.comContext Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Rating of "Buy" by AnalystsContext Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) has been assigned a consensus recommendation of "Buy" from the seven brokerages that are currently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy ratinApril 20, 2025 | marketbeat.comContext Therapeutics Inc. (NASDAQ:CNTX) Stock Holdings Trimmed by Affinity Asset Advisors LLCAffinity Asset Advisors LLC lessened its position in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 23.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,015,340 shares of the compaApril 17, 2025 | marketbeat.comFranklin Resources Inc. Purchases 2,149,392 Shares of Context Therapeutics Inc. (NASDAQ:CNTX)Franklin Resources Inc. lifted its position in Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 115.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,003,380 shares of the compaApril 14, 2025 | marketbeat.comContext Therapeutics (NASDAQ:CNTX) Receives "Buy" Rating from D. Boral CapitalD. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Context Therapeutics in a report on Wednesday.April 11, 2025 | marketbeat.comContext Therapeutics doses first patient in Phase 1 trial of CT-95April 10, 2025 | markets.businessinsider.comContext Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing CancersApril 10, 2025 | msn.comContext Swoons on CT-95 First DoseApril 9, 2025 | baystreet.caContext Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95April 9, 2025 | globenewswire.comContext Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95April 9, 2025 | globenewswire.comZacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and LeidosApril 4, 2025 | finance.yahoo.comContext Therapeutics to Participate in Upcoming Investor ConferencesApril 1, 2025 | globenewswire.comContext Therapeutics to Showcase CT-95 Data at AACR 2025March 28, 2025 | msn.comContext Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025March 26, 2025 | globenewswire.com Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTX Media Mentions By Week CNTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTX News Sentiment▼0.000.68▲Average Medical News Sentiment CNTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTX Articles This Week▼02▲CNTX Articles Average Week Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BTMD News INBX News MNPR News SCPH News GNFT News IMAB News CRGX News FDMT News PRQR News DRUG News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTX) was last updated on 6/20/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Biggest Story of My Decade-Long Career in Silicon ValleySteve Jobs' Lost 'Product' Could Save Tesla On July 21st, a revolutionary announcement could transform Tesl...InvestorPlace | SponsoredA grave, grave error.It seems like the world is on fire. Trump’s tariffs are crippling economies worldwide. Canada’s been cri...Porter & Company | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
